June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
LRG1-driven phenotypic switch in pericytes is an early event in diabetic retinopathy
Author Affiliations & Notes
  • Giulia De Rossi
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Marlene E Da Vitoria Lobo
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • John Greenwood
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Stephen E Moss
    Institute of Ophthalmology, University College London, London, London, United Kingdom
  • Footnotes
    Commercial Relationships   Giulia De Rossi None; Marlene Da Vitoria Lobo None; John Greenwood PanAngium Therapeutics, Code O (Owner), PanAngium Therapeutics, Code P (Patent); Stephen Moss PanAngium Therapeutics, Code O (Owner), PanAngium Therapeutics, Code P (Patent)
  • Footnotes
    Support  Diabetes UK
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 414. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Giulia De Rossi, Marlene E Da Vitoria Lobo, John Greenwood, Stephen E Moss; LRG1-driven phenotypic switch in pericytes is an early event in diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2022;63(7):414.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Pericytes have a fundamental role in maintaining vascular homeostasis and their malfunction is thought to be an early event in diabetic retinopathy (DR). Cross-sectional studies have reported increased levels of leucine-rich α-2 glycoprotein 1 (LRG1) in the plasma and vitreous humor of diabetic patients but failed to establish whether LRG1 plays an active role in disease pathogenesis. Our study aimed to elucidate the role of LRG1 in the early microvascular events taking place in the diabetic retina using experimental models of DR.

Methods : We took advantage of two murine models of type I diabetes (STZ and Akita) to correlate Lrg1 expression to the retinal vascular changes happening over 6 months of hyperglycaemia. We also compared global Lrg1-deficient mice to wild-type littermates to identify the contribution of LRG1 to the vascular abnormalities in diabetic retinas (N=10/group, males, C57Bl/6). We then designed in vitro culture models incorporating human primary retinal pericytes (HRP) to assess the effects of LRG1 on the morphology, signalling and function of pericytes (N=3).

Results : We found increased LRG1 expression in diabetic retinas early after hyperglycaemia onset (4-8 wks). In both models, diabetic retinas were characterised by an increased number of semi-detached pericytes (or ‘pericyte bridges’), stretching their processes between adjacent capillaries of the deep plexus (50% increase at 16 wks). This increase did not occur in the diabetic retinas of Lrg1-deficient mice. Morphometric analyses revealed that these hyper-activated pericytes, and their processes, were almost-exclusively associated with bent capillaries (Fig.), suggesting that these structures can exert tractional forces on endothelial cells (ECs). Based on these observations, we subjected cultured HRPs to increasing doses of recombinant LRG1 and revealed a phenotypic switch towards a more star-shaped morphology coupled to an enhanced ability to contract collagen type I. This contractile phenotype was associated with increased expression of typical myofibroblast proteins (αSMA, vimentin, fibronectin).

Conclusions : We have shown that LRG1 is up-regulated early on after hyperglycaemia onset in the retina and triggers a myofibroblastic-like phenotype in pericytes. We believe that targeting LRG1 could prevent or revert EC-pericyte decoupling and normalise the vasculature, paving the way to more timely and effective treatments in DR.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×